Ads
related to: vesicare indication- Female Bladder Health
Regain Bladder Control & Confidence
Tips for Supporting Bladder Care
- Watch: Bladder Care Tips
See Ways to Support Bladder Health
Free Natural Bladder Support Guide
- At-Home Care Guide
Begin Your Journey in Privacy
Simple Methods to Try at Home
- Bladder Care Video Guide
Watch Simple Methods at Home
Begin From the Privacy of Your Home
- Female Bladder Health
Search results
Results from the WOW.Com Content Network
Solifenacin, sold as the brand name Vesicare [a] among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). [1] [2] It may help with incontinence, urinary frequency, and urinary urgency. [3] Benefits appear similar to other medications in the class. [4] It is taken by mouth. [1]
Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab: Remicade Biologic ...
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder.It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.
Here vibegron differs from the previous overactive bladder drug mirabegron, which was known to be associated in various drug–drug interactions by inhibiting CYP2D6 or inducing CYP3A4, CYP2D6 and CYP2C9 in the liver. [13] [4] [14] [15] [16] [17]
Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. [8] [9] [3] In 2022, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Ads
related to: vesicare indication